Next Article in Journal
Neural and Hormonal Basis of Opposite-Sex Preference by Chemosensory Signals
Next Article in Special Issue
Deletion of Neuronal CuZnSOD Accelerates Age-Associated Muscle Mitochondria and Calcium Handling Dysfunction That Is Independent of Denervation and Precedes Sarcopenia
Previous Article in Journal
The Gut Microbiota-Derived Immune Response in Chronic Liver Disease
Previous Article in Special Issue
The Neuromuscular Junction: Roles in Aging and Neuromuscular Disease
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 22
Issue 15
10.3390/ijms22158310
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Natural Compounds Attenuate Denervation-Induced Skeletal Muscle Atrophy

by
Tomohiko Shirakawa
1,2,
Aki Miyawaki
2,
Tatsuo Kawamoto
1 and
Shoichiro Kokabu
2,*
1
Division of Orofacial Functions and Orthodontics, Department of Health Improvement, Kyushu Dental University, Kitakyushu, Fukuoka 803-8580, Japan
2
Division of Molecular Signaling and Biochemistry, Department of Health Improvement, Kyushu Dental University, Kitakyushu, Fukuoka 803-8580, Japan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2021, 22(15), 8310; https://doi.org/10.3390/ijms22158310
Submission received: 21 June 2021 / Revised: 29 July 2021 / Accepted: 29 July 2021 / Published: 2 August 2021
(This article belongs to the Special Issue Skeletal Muscle Denervation)
Browse Figures
Review Reports Versions Notes

Abstract

:
The weight of skeletal muscle accounts for approximately 40% of the whole weight in a healthy individual, and the normal metabolism and motor function of the muscle are indispensable for healthy life. In addition, the skeletal muscle of the maxillofacial region plays an important role not only in eating and swallowing, but also in communication, such as facial expressions and conversations. In recent years, skeletal muscle atrophy has received worldwide attention as a serious health problem. However, the mechanism of skeletal muscle atrophy that has been clarified at present is insufficient, and a therapeutic method against skeletal muscle atrophy has not been established. This review provides views on the importance of skeletal muscle in the maxillofacial region and explains the differences between skeletal muscles in the maxillofacial region and other regions. We summarize the findings to change in gene expression in muscle remodeling and emphasize the advantages and disadvantages of denervation-induced skeletal muscle atrophy model. Finally, we discuss the newly discovered beneficial effects of natural compounds on skeletal muscle atrophy.

1. Introduction

Skeletal muscle atrophy is the loss of the volume of skeletal muscle, leading to the weakness of muscle and causes disability. Skeletal muscle atrophy is known to be caused by immobility, aging, malnutrition, medication, or a wide spectrum of injuries or diseases that impact the nervous or musculoskeletal system. Sarcopenia was firstly described in 1989 as an age-related decrease in lean body affecting nutritional status, mobility, and independence [1]. Now, sarcopenia is defined as a progressive and generalized skeletal muscle disorder which involves the accelerated loss of muscle mass and function [2]. Thus, the definition of sarcopenia includes muscle loss related to physical inactivity, chronic disease, and malnutrition [3]. When age-related, it is known as primary sarcopenia. On the contrary, sarcopenia due to chronic disease or loss of mobility is called as secondary sarcopenia. However, this distinction is sometimes difficult because older patients sometimes present with both [4]. Sarcopenia is prevalent worldwide [5] and is recognized as a disease by the World Health Organization and included in the International Classification of Disease (ICD code M62.8) [6]. Therefore, skeletal muscle research has been actively conducted in recent years. However, therapeutic methods have not been established for skeletal muscle atrophy.
Sarcopenia has also occurred in the muscle of the head, neck, and maxillofacial region. Oral frailty, which impairs oral function, induces a high mortality rate [7]. The concept of oral frailty partially overlaps with sarcopenia of the muscle related to speaking, chewing, and swallowing [8]. In addition, facial muscle abnormalities cause facial and systemic disorders because skeletal muscles are involved in normal maxillofacial growth and malocclusion [9,10]. It is interesting to note that the developmental process and gene expression of facial muscles are different from that of other muscles [11,12,13].
Here, we summarize the muscle specificity in the maxillofacial region and emphasize the unique features of the maxillofacial region. We also explain the molecular mechanism of muscle development, anabolism, and catabolism. In addition, we focus on the sciatic nerve denervation model as a skeletal muscle atrophy model. Finally, we introduce foods that have been shown to be effective against skeletal muscle atrophy and discuss their usefulness.

2. Maxillofacial Problems Caused by Muscle Atrophy

Sarcopenia affects the maxillofacial region. Maxillofacial problems caused by muscle atrophy include oral frailty, malocclusion, and inhibition of normal growth and development.
In recent years, attention has been paid to the decline in oral function known as oral frailty; muscle weakness in the maxillofacial region can affect dysphagia and communication, while oral frailty has also been reported to have a high mortality rate [7].
Maxillofacial muscles and dentition are closely related. The dentition is aligned in accordance with the muscle pressure exerted by the orbicularis oris, buccinator, and tongue muscles [10]. Thus, when muscle pressure imbalances occur, malocclusion occurs (Figure 1).
For example, patients with muscular dystrophy have a lower tongue position than that seen commonly because of weakness of the lingual muscles. As a result, the maxillary arch narrows because of reduced tongue pressure. In addition, weakness of the masticatory muscles causes the mandible to lower downwards, resulting in supra-eruption of the molars. Therefore, it causes an anterior open bite.
Muscle weakness adversely affects the growth and development. Moss proposed functional matrix theory, which states that non-bone tissue induces bone growth in facial growth [9]. The growth of the membranous neurocranium and the naso-maxillary complex is regulated by environmental factors such as organ position and size, as well as the influence of soft tissues and teeth. Conversely, cartilage growth in the cartilage neurocranium, nasal septum, and mandibular condyle is highly regulated by genetic factors. A normal functional matrix is essential for obtaining a normal morphology. Craniofacial muscle weakness during growth hinders growth and development. In progressive facial hemiatrophy, muscle atrophy occurs unilaterally, resulting in facial asymmetry. Even after the growth is complete, deformation of the mandible can be caused by a mechanical imbalance in the masticatory muscles [14,15,16]. Moreover, masseter muscle removal [17] and masseter muscle damage [18] can cause mandibular asymmetry.
Muscles are also important factors in patients with jaw deformities. Patients with skeletal mandibular protrusion have low levels of myosin heavy chain (MyHC) expression [19], which may be attributed to the small occlusal contact points in patients with mandibular protrusion. Muscle effects have also been suggested to result in relapse after orthognathic surgery [20,21,22,23,24], however in contrast, it is interesting that the movement of bone fragments causes a change in the occupancy of the MyHC isoform. The masseter muscle usually has a high proportion of type I fibers; after orthognathic surgery, the proportion of type I fibers decreased and that of type II fibers increased [25,26,27]. Similarly, type I to type II conversions also occur at limb muscles due to severe deconditioning or spinal cord injury [28,29]. Decreased use of skeletal muscle has been reported in switching muscle fiber types from slow to fast [28], and it is difficult to determine whether it results from damage to the skeletal muscles, innervation caused by orthognathic surgery, or from intermaxillary fixation after orthognathic surgery. Interestingly, the gene expression level changes depending on the movement direction of the mandible (anterior or posterior movement) [20,21]. Muscle extension is thought to be caused by the movement of bone fragments.
Therefore, prevention and early treatment of muscle atrophy are required because muscle properties affect maxillofacial morphology and function. However, there are many unclear points about muscular atrophy in the maxillofacial region, and further research is needed.

3. Difference in Gene Expression between Facial and Other Muscles

In recent years, it has become clear that facial muscles and trunk muscles have significantly different properties even if they are the same type of muscle. In development, the facial muscles originate from the branchial arch, whereas the trunk muscles originate from the somites. In addition, the genes expressed in facial muscles and trunk muscles are different. Myogenic factor 5 (Myf5), myoblast determination protein 1 (MyoD), and paired box protein 7 (Pax7) are expressed in both muscles, but mesoderm posterior 1 (Mesp1) is found in facial muscles and Pax3 is found in trunk muscles [13]. However, expression of both Mesp1 and Pax3 has been confirmed in the muscles of tongue. Further, the gene expression of the facial muscles differs depending on the site, such as Myf5 in the eye muscles and Myf5/insulin gene enhancer protein (ISl1) in the masticatory muscles [30].
The reaction to muscle atrophy differs between facial and somatic muscles. It is known that in mature muscle tissue, facial muscles are less prone to cause muscle atrophy than somatic muscles in patients with muscular dystrophy. It had been thought that this is because the muscles of the face frequently contract to breathe and swallow. However, it was suggested that resistance to skeletal muscle atrophy may differ. Yoshioka et al. showed differences in muscle atrophy and regenerative ability between facial and trunk muscles using a skeletal muscle atrophy model [31]. In addition, the composition of the MyHC isoforms differs. It has been shown that expression of MyHC 2a is not observed in the masseter muscle in adult mice [32]. The characteristics of MyHC isoform are summarized in Table 1 [33,34,35].
In human masseter muscles, MyHC 2x are high expression. Interestingly, MyHC NEO is expressed in adult human masseter muscles [33]. In the trunk and limbs, MyHC NEO is usually expressed only during development and regeneration [33]. Satellite cells and muscle tissue stem cells are functionally heterogeneous populations in both masseter and limb muscles [36].
Due to differences in mechanism and characteristics, a site-specific approach may be required for muscle treatment. Research on the difference between facial muscles and trunk muscles is desired.

4. Molecular Mechanism of Muscle Homeostasis

4.1. Intracellular Signaling of Skeletal Muscle Anabolism

Insulin-like growth factor 1 (IGF-1) is mainly secreted from the liver and promotes the growth and proliferation of skeletal muscles. The mammalian target of rapamycin (mTOR) is a protein that plays a central role in the control of catabolism and anabolism, such as translation of mRNA, promotion of cell growth, and suppression of autophagy. There are rapamycin-sensitive mTOR complex 1 (mTORC1) that binds Raptor and rapamycin-non-sensitized mTOR complex 2 (mTORC2) that binds Rictor [37]. Protein kinase B (Akt) indirectly stimulates mTORC1. mTORC2 is required for phosphorylation of Akt [38]. Binding IGF-1 to the IGF-1 receptors leads to activation of mTORC1 via intracellular phosphoinositide 3-kinase (PI3K) and Akt. Conversely, when energy decreases, that is, when adenosine monophosphate (AMP) concentration increases, AMP-activated protein kinase (AMPK) is activated and protein synthesis is suppressed by negatively controlling mTORC1 activity [39]. mTORC1 promotes protein synthesis by suppressing eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4EBP1) and activating ribosomal protein S6 kinase-1 (S6K1), which regulate mRNA translation [40]. 4EBP1 inhibits eIF4E activity.
Satellite cells are the most abundant tissue stem cells resided in skeletal muscle; they are generally recognized for their contributions to regeneration, hypertrophy, and maintenance of muscle mass during the life span [41]. Pax7 is highly expressed in quiescent satellite cells, and MyoD expression is increased when cells are activated. Some satellite cells self-replicate and return to the quiescent phase, while others become myoblasts that express myogenin and cause muscle differentiation. Satellite cells are necessary for postnatal skeletal muscle growth, and trigger cytokines are secreted not only by inflammatory cells but also by muscle fibers, blood vessels, and motor neurons [42]. The trigger molecule has various factors such as IGF-1, interleukin-6 (IL-6), transforming growth factor β (TGF-β), and fibroblast growth factor (FGF), and is controlled intricately. IL-6 stimulation in skeletal muscle increases cyclin D1 expression via janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling, while IL-6, which is excessive due to chronic inflammation, suppresses satellite cell proliferation via JAK2/STAT3 signaling [43].

4.2. Intracellular Signaling of Skeletal Muscle Catabolism

Protein degradation system in muscle cells include the lysosomal system, the calpain system, and the ubiquitin-proteasome system. The ubiquitin-proteasome system consists of a ubiquitination system, which is comprised of ubiquitin activating enzyme (E1), ubiquitin binding enzyme (E2), and ubiquitin ligase (E3), and the 26S proteasome system that decomposes poly-ubiquitin [44]. The muscle-specific E3 ubiquitin ligases atrogin-1 and muscle ring finger 1 (MuRF-1) are upregulated in various muscle atrophy models. Forkhead box O (Foxo) is known as the gene that regulates the expression of atrogin-1 and MuRF-1. Foxo1 transgenic mice show decrease in muscle mass [45]. Atrogin-1 null mice and MuRF-1 null mice have been shown to suppress denervation-induced skeletal muscle atrophy [46].
Akt, which is activated by IGF-1, phosphorylates Foxo and suppresses the transcriptional activity of Foxo. Conversely, AMPK phosphorylates different sites of Foxo and increases the transcriptional activity [47]. The nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κB), which is activated during inflammation, also promotes the induction of MuRF-1 expression [48]. Tumor necrosis factor α (TNF-α) also increases MuRF-1 expression via NFκB [49]. In addition, TNF-α increases Foxo activity by inhibiting the IGF1-Akt pathway via c-jun N-terminal kinase (JNK) [50].
Peroxisome proliferator-activated receptor gamma coactivator 1 (PGC1-α), which is a transcription conjugate factor, decreases when exercise is insufficient or inactive. A decrease in PGC1-α reduces phosphorylation of Foxo [51]. In addition, Casitas B-lineage lymphoma-b (Cbl-b) has been reported as a E3 ubiquitin ligase whose expression is highly increased in atrophic muscles. Cbl-b specifically binds to insulin receptor substrate-1 (IRS-1) to enhance ubiquitination and degradation, thus diminishing the IGF-1 signal [52,53]. It was confirmed that a peptide called Cblin, which is a Cbl-b inhibitor, inhibits the degradation of IRS-1 in the gastrocnemius muscle of mice undergoing sciatic nerve resection and suppresses the expression of muscle atrophy-related genes [53]. Cbl-b can be a treatment for skeletal muscle atrophy.
Myokines are secreted by skeletal muscles, some of which act on other organs and some of which act on the skeletal muscle itself. IGF-1, FGF-2, and IL-6 also act as myokines [54]. Myostatin, a member of the TGF-β superfamily, is secreted by skeletal muscle and has been reported as a factor that negatively regulates muscle growth [55]. Myostatin activates Smad2/3 via activin type II B receptors (ActRIIB) on the cell surface. Smad2/3 forms a heterodimer with Smad4. Smad2/3/4 regulates cell proliferation by controlling the expression of p21 and cyclin-dependent kinase 2 (CDK2). It also controls the expression of Pax7, MyoD, and myogenin to suppress muscle differentiation. In addition, phosphorylated Smad2/3 acts on Akt to inhibit mTORC1 activation and Foxo inactivation and negatively regulates protein levels [56].

5. Denervation Animal Model

The denervation model is a popular mechanism of skeletal muscle atrophy [57,58,59,60], where the sciatic nerve is usually removed. The reason is that nerves can be easily removed, surgery can be performed without damaging the tissue to be analyzed, and normal raising is possible after the surgery [61]. By analyzing the muscles (tibialis anterior muscle, gastrocnemius muscle, and extensor digitorum longus muscle) in the sciatic nerve innervation region, denervation-induced skeletal muscle atrophy is evaluated. Denervation-induced skeletal muscle atrophy upregulates the lysosome, calpain, and ubiquitin-proteasome systems [46,62,63]. The denervation model is useful for inducing major mechanisms of skeletal muscle catabolism.
The advantage of the denervation model is that both an experimental group and a control group can be secured in the same animal [61]. By performing sciatic nerve denervation treatment on the experimental side and sham surgery on the opposite side, it is possible to ensure that muscles with and without atrophy can coexist in the same animal. It is beneficial for researchers to be able to eliminate the variability that occurs between individuals.
There are some things to consider in the denervation model. While skeletal muscle atrophy is induced by removing the sciatic nerve, there is a neuropathic pain model using the same method. According to the neuropathic pain model, it may cause self-harm on the affected limb, and it is necessary to observe excessive self-harm when evaluating the muscular atrophy model [64]. Further, the sciatic nerve denervation model is used as an osteoporosis model [65]. The prevalence of sarcopenia and osteoporosis has been reported to be correlated, and it has been suggested that myokine affects bone [66]. In recent years, it has been suggested that osteokine secreted by bone tissue affects the whole body [54]. These reports mean that the denervation-induced skeletal muscle atrophy model does not merely reflect skeletal muscle atrophy; it suggests that it is affected by neural transmission, trophic substances, and secretions from bone tissue.
Moreover, not all mechanisms of muscle atrophy can be elucidated by the denervation model. Other animal models include the hind limb unloading and immobilization models, while the hind limb unloading model induces skeletal muscle atrophy by lifting the legs. This model induces skeletal muscle atrophy similar to the microgravity-like space area. The immobilization model imitates bedrest and induces muscle atrophy in immobile legs using casts. These models differ in the mode of skeletal muscle atrophy. For example, in the space area, the rat soleus muscle undergoes severe atrophy, but the tibialis anterior muscle shows less atrophy [67]. In the immobilization model, protein degradation by lysosomes was lower than that in the other models [68]. These reports differ from that of denervation-induced skeletal muscle atrophy. The use of other models is considered for skeletal muscle atrophy under these specific conditions.
While some molecular mechanisms are common among skeletal muscle atrophy models, there are specific mechanisms to denervation-induced skeletal muscle atrophy. Activation of mTORC by denervation stimulates S6K, resulting in suppression of IRS-1 as a negative feedback effect, and it has been suggested that Foxo-upregulation occurs as a result [69]. In addition, it has been shown that muscle atrophy occurs even if myostatin is inhibited during denervation, and muscle fibers do not recover. In contrast, the immobilization model has been shown to suppress muscle atrophy by inhibiting myostatin, which shows that there are differences in the mechanism of muscle atrophy models [57]. Further detailed molecular mechanisms are expected to be elucidated in future.
Furthermore, attention should be paid to skeletal muscle atrophy in the craniofacial region. As mentioned earlier, the development pattern is different between the facial and limb muscles. The limb muscles are controlled by the motor nerves from the spinal cord, while the facial muscles are controlled by the cranial nerves. The orbicularis oris and buccinator muscles are controlled by the facial nerve (cranial nerve VII), and facial nerve axotomy models have been established [70]; however, studies on facial muscle atrophy are insufficient. In the future, it is necessary to investigate whether gene expression differs from that of somatic muscle during muscle atrophy of facial muscles.
The denervation model is considered to be the following disease model. Spinal muscular atrophy, amyotrophic lateral sclerosis, and neuralgic amyotrophy are caused by motor nerve degeneration, and because these diseases impair facial muscle movement and swallowing, the sciatic nerve denervation model may be useful for elucidating the mechanism of muscular atrophy in maxillofacial region. These diseases indicate a poor prognosis. Motor nerve degeneration or denervation occurs not only in congenital diseases but also in acquired factors (for example, injuries, virus infection, and surgery). Denervation is thought to contribute to sarcopenia, because motor innervation of skeletal muscle decreases with aging [71]. Sarcopenia affects other diseases, with osteoporosis [72,73], bone fractures [74], critical limb ischemia [75], diabetes [76], cognitive decline [77], and cancer [78,79,80] showing a higher predilection in sarcopenia. In other words, an increase in skeletal muscle mass is important for the prevention of various diseases. Therapy and prevention of skeletal muscle atrophy need to intervene the catabolic downregulation and/or anabolic upregulation. Currently, however, there are no therapeutic strategies to approach the muscle remodeling cycle (Figure 2).
This schema is muscle remodeling cycle. Increasing muscle anabolism (proliferation, differentiation, muscle hypertrophy) and reducing catabolism are necessary against skeletal muscle atrophy. Satellite cells are stimulated by damaged-myofiber-derived factors from the muscle tissue [81]. This cycle is also affected by hormones, myokines, osteokines, and adipokines.

6. Natural Compounds (Effective Foods against Denervation-Induced Skeletal Muscle Atrophy)

There are a wide variety of pathologies that cause skeletal muscle atrophy. However, many factors, such as hereditary diseases and sarcopenia, are currently difficult to eliminate. In addition, the muscle remodeling cycle is fast, and long-term treatment is necessary to maintain muscle mass. Therefore, if skeletal muscle atrophy can be prevented by food, it would be an effective population approach. These diets are safe, inexpensive, and can be incorporated into daily intake. In addition, since food can cause allergies, it is necessary to find as many foods as possible that can counteract skeletal muscle atrophy.
The following is a summary of effective foods against denervation-induced skeletal muscle atrophy.

6.1. Royal Jelly (RJ)

Honeybees (e.g., Apis mellifera) excrete RJ from cephalic glands. RJ is the main source of nutrition for queen honeybees; they are larger, with a longer life span than other honeybees, while RJ affects the fertility of queen honeybees [82,83]. It has been reported to prolong life span [84,85], reduce fatigue [86], and have antioxidant and anti-inflammatory properties [87,88,89]. In humans, RJ reduces serum cholesterol and lipid levels [90].
The components of RJ include water (60–70%), proteins (9–18%), sugars (7.5–23%), lipids (3–8%), and other trace compounds. RJ contains 60–80% trans-10-hydroxy-2-decenoic acid (10H2DA) and 10-hydroxydecanoic acid (10HDAA) in lipids [91]. In animal experiments, 10H2DA and 10HDAA were found to be pharmacologically beneficial [92,93,94,95,96].
RJ affects skeletal muscle metabolism. In mice experiments, RJ induces regeneration of damaged skeletal muscle by satellite cells via the IGF-1-Akt pathway [97] and activation of AMPK by endurance training [98]. RJ removed protein (protease-treated RJ [pRJ]) also had a positive effect on skeletal muscle. Daily oral administration of pRJ prevents denervation-induced skeletal muscle atrophy [99], and it has been reported that pRJ affects muscle fiber thickness, expression of satellite cell catabolic gene, and proliferation and differentiation in C2C12 myoblasts [99,100].
Although it is known that RJ suppresses skeletal muscle atrophy, a detailed mechanism has not been revealed. RJ is known to regulate epigenetic changes [101]. RJ and 10H2DA suppressed histone deacetylase (HDAC)-activity without affecting DNA methylation [102]. Inhibition of HDAC and DNA methyltransferases upregulates myogenesis [103,104,105,106]. The epigenetic effects of RJ should be further investigated and need to be examined for changes in gene expression.
RJ upregulates IGF-1, IGF receptors, and pAMPK. Activation of Akt and AMPK translocate glucose transporter type 4 (GLUT4) to the cell membrane [107]. 10H2DA, an RJ-specific fatty acid, activates AMPK in skeletal muscles [108]. Mitochondrial activity in skeletal muscle is related to insulin resistance and is important for preventing sarcopenia. These studies suggest a therapeutic approach to glucose tolerance with decreased skeletal muscle.
The beneficial effects of RJ have only been partially elucidated. In future, a detailed downstream analysis of RJ-specific components is required.

6.2. Geranylgeraniol (GGOH)

GGOH is a C20 isoprenoid found in fruits, vegetables, and grains. GGOH falls under the category of “Generally recognized as safe (GRAS)” for consumption [109]. GGOH is an intermediate product of the mevalonate pathway and functions as a precursor of geranylgeranylpyrophosphate (GGPP).
Matsubara et al. showed that GGOH enhances C2C12 myoblast differentiation in vitro, but high doses of GGOH tend to suppress myoblast proliferation [110]. Miyawaki et al. reported that GGOH administration increased the muscle fiber size in denervation-induced skeletal muscle atrophy in vivo [111]. GGOH also suppresses the denervation-induced or glucocorticoid-induced atrogin-1 expression [111]. Expression of atrogin-1 is increased when muscle atrophy is induced by the stressors [112]. Suppressing atrogin-1 expression is important to prevent skeletal muscle atrophy.
Many studies have shown the role of NF- κB in the induction of muscle atrophy [48,113,114,115,116,117]. NF- κB upregulates atrogin-1 expression [118]. GGOH treatment decreases lipopolysaccharide (LPS)-induced NF- κB signaling [119,120]. GGOH has also been demonstrated to upregulate testosterone synthesis in testis-derived cells [121]. Testosterone is a steroid hormone that is strongly involved in muscle metabolism [122]. Androgen and testosterone promote muscle hypertrophy and suppress the expression of atrogin-1 and MuRF-1 [123,124]. Therefore, NF- κB signaling and/or testosterone may participate in the suppression of skeletal muscle atrophy by GGOH.
Statins are used to prevent cardiovascular disease [125,126,127,128] and inhibit cholesterol synthesis via the mevalonate pathway. However, they may induce muscle cell damage and severe rhabdomyolysis [129,130,131,132]. Statin-associated muscle disorders may reduce crucial intermediary molecules such as GGPP by inhibiting the mevalonate pathway [133,134,135]. Treatment of C2C12 cells with GGPP reverses the inhibitory effect of statins on myotube formation [136]. Cao P et al. reported that GGOH treatment reduces the expression levels of atrogin-1 that is induced by statins in vitro [137].
GGOH is inexpensive, classified as GRAS, and can be administered orally. In future, a detailed downstream analysis of GGOH is required on skeletal muscle metabolism.

6.3. Soybeans

Soybeans are grown in many countries for food, fertilizer, and oil production. The components of soybeans include proteins (33.8%), sugars (29.5%), lipids (19.7%), water (12.4%), and other trace compounds [138]. Soy protein has been reported to promote increased skeletal muscle mass and strength in humans [139].
Long-term administration of soy protein increased the number of satellite cells and differentiated cells (pax7− myoD+) in ovariectomized mice [140]. Glycinin is a major protein contained in soybeans [141]. Glycinin has an amino acid sequence similar to that of Cblin. When the muscle atrophy inhibitory effect of glycinin in denervation mice was examined, it was confirmed that it suppressed the decrease in the muscle wet weight of the tibialis anterior muscle and suppressed the decrease in muscle cross-sectional area [142]. A mixed diet of soy protein and whey protein showed a strong inhibitory effect on denervation-induced skeletal muscle atrophy [143]. In addition, it has been reported that soy protein isolate and red bell pepper juice suppressed skeletal muscle atrophy in denervated mice [144]. Whey protein is known to stimulate muscle protein synthesis via mTOR signaling in humans [145]. It has been reported that ingestion of soy protein also increases muscle mass in human with low physical activity [139].
Soybeans are nutritious and contain the isoflavones described in the next section. It is necessary to determine the components that act on the skeletal muscles.

6.4. Polyphenol

Polyphenol is a compound containing multiples of phenol units contained in plants. Various uses of polyphenols have been reported, including effective substances on muscle atrophy in recent years.
Isoflavones are one of the flavonoids and are natural organic compounds. Administration of isoflavones suppresses denervation-induced apoptosis and muscle atrophy [146,147]. It has been reported that isoflavones can suppress the transcriptional activity of MuRF-1 induced by TNF-α and myotube atrophy [148]. In addition, isoflavones suppress the damage of acetylcholine receptors through denervation. It has been suggested that they have a protective effect on neuromuscular junctions [147].
Isoflavones are known to act as phytoestrogens. Women who consumed isoflavones for 24 weeks had an increased muscle mass index [149]. Estrogen receptors (ER) include ERα and ERβ. Daidzein, a soy isoflavone, has been shown to have more effect on ERβ than on Erα [150]. ERβ is involved in the synthesis and degradation of skeletal muscles. It has been shown to promote muscle fiber growth via Erβ [151]. In addition, it was clarified that it is responsible for the inhibition of satellite cell proliferation and cell death via Erβ [151]. A decrease in the blood levels of sex hormones that occur in old age leads to a decrease in skeletal muscle. Daidzein may be effective in older women, and in addition, 8-prenylnaringenin, which has an estrogenic effect like daidzein, suppresses denervation-induced skeletal muscle atrophy, and its effect is thought to be due to phosphorylation of Akt [152]. These estrogenic isoflavones may be effective not only for skeletal muscle atrophy, but also for postmenopausal disease.
Quercetin is a flavonoid contained in fruits and vegetables, and has a strong radical scavenging ability. Reactive oxygen species (ROS) are generated during the process of ATP production in mitochondria. ROS causes cell damage and is involved in the disease [153,154,155]. ROS activates the NFκB and Foxo pathways and induces the expression of E3 ubiquitin ligase [156,157]. Research is ongoing on the concept that substances with antioxidant activity suppress ROS and muscle atrophy. In the hind limb unloading model, administration of quercetin to the gastrocnemius muscle reduced atrogin-1 and MuRF-1 expression and suppressed the loss of skeletal muscle mass [158]. Administration of quercetin promotes phosphorylation of Akt and suppresses skeletal muscle atrophy [159].

6.5. Vitamins

Vitamins are nutrients that cannot be synthesized in sufficient amounts in the body, and are organic compounds excluding the three major nutrients. Insufficient vitamin intake has systemic effects but is also an important factor in skeletal muscle.
Vitamin C is a cofactor involved in the synthesis of collagen. Vitamin C is usually considered to have an antioxidant effect and eliminates ROS [160]. However, some reports show that vitamin C have prooxidant effect [161,162]. It was reported that elderly women with high concentration of vitamin C had high muscle strength and physical ability [163]. When genetically modified mice that could not biosynthesize vitamin C were used, vitamin C deficiency reduced muscle weight and increased expression of Foxo-1, Cbl-b, atrogin-1, and MuRF-1. Further, re-administration of vitamin C rescued muscle weight and reduced skeletal muscle atrophy gene expression [164]. Conversely, Makanae et al. reported that the supplementation of vitamin C suppresses the hypertrophy of muscle by overloading [165]. Like that, the function of vitamin C in muscle metabolism is controversial and may be different depending on the physical status.
Vitamin D is involved in calcium absorption and utilization and bone calcification, but in recent years it has been suggested that it may also play an important role in skeletal muscle [166]. In mice, deletion of vitamin D receptor reduces muscle fiber size [167]. Low levels of vitamin D in the blood reduce muscle strength and increase the risk of sarcopenia [168]. There is also a report that vitamin D administration restores muscle strength [169]. In experiments using C2C12 cells, vitamin D suppressed the expression of atrogin-1 and cathepsin L [170]. These literatures also showed that the supplementation of vitamin D is effective only in the condition of vitamin D deficiency.
Vitamin E has an antioxidant effect similar to that of vitamin C; therefore, it is expected to remove ROS. In the Unload model, vitamin E reduced the expression of atrogin-1 and MuRF-1 and suppressed skeletal muscle atrophy [171]. In this study, muscular atrophy suppression is not due to an antioxidant effect. In contrast, there are reports that vitamin E has no suppressive effect on muscular atrophy [172].

6.6. Capsaicin

Capsaicin is a pungent ingredient contained in chili peppers. The capsaicin receptor transient receptor potential vanilloid 1 (TRPV1) is known as a pain receptor. It was reported that TRPV1-mediated Ca2+ signaling activates mTOR and promotes muscle hypertrophy [173]. However, the stimulation of TRPV1 causes pain; therefore, it seems difficult to apply it as a food approach.
Figure 3 shows how natural compounds are effective in muscle remodeling cycle and Table 2 summarizes the studies to examine the effect of natural compounds on skeletal muscle atrophy in human and animal model. Unfortunately, no studies have reported the function of natural compounds on maxillofacial muscle atrophy and sarcopenia. Special attention and research on maxillofacial muscle should be required immediately. Because the malnutrition by the problems of occlusion and/or swallowing may contribute to the loss of whole body muscles.
These are natural compounds that suppress denervation-induced skeletal muscle atrophy. In other words, they induce the increasing muscle anabolism and/or decreasing muscle catabolism. The mechanism of suppressing skeletal muscle atrophy differs depending on the foods. RJ: Royal jelly, GGOH: Geranylgeraniol.
Table
Table 2. Studies for the function of natural compounds on skeletal muscle metabolism.
Table 2. Studies for the function of natural compounds on skeletal muscle metabolism.
ReferencesSpeciesNatural CompoundsPhenotype, Intervention/
Key Findings
Niu K
et al. [97]		miceRoyal jelly
(RJ)		C57BL/6J mice, aged mice/
Suppression of decrease muscle weight and grip strength
Increase the regeneration of injured muscles and the serum insulin-like growth factor-1 (IGF-1)
Takahashi Y
et al. [98]		miceRJICR mice, training/
RJ induces mitochondrial adaptation with endurance training by AMP-activated protein kinase (AMPK) activation
Shirakawa T
et al. [99]		miceRJC57BL/6J mice, denervation/
Suppression decrease muscle fiber size by oral administration
Okumura N
et al. [100]		miceRJGenetically heterogeneous mice, aged mice/
Motor function
Increase fiber size
Increase proliferation and differentiation
Takikawa M
et al. [108]		mice10H2DAC57BL/6J mice, oral adnimistration/
Stimulated phosphorylation of AMPK
Glucose transporter type 4 (Glut4) translocation to the plasma membrane
Miyawaki A
et al. [111]		miceGeranyl-geraniol
(GGOH)		C57BL/6J mice, denervation/
Suppression decrease muscle fiber size and expression of atrogin-1
Hashimoto R
et al. [139]		HumansSoy proteinHigh and low physical activity, food intake/
Increase skeletal muscle mass in low activity human
Kitajima Y
et al. [140]		micesoymilkC57BL/6 mice, ovariectomized mice/
Muscle fiber hypertrophy
Increase grip strength
Abe T
et al. [142]		miceSoy glycininC57BL/6J mice, denervation/
Increase fiber diameter
Suppression expression of muscle atrogene via IGF-1 signaling
Nikawa T
et al. [143]		miceSoy protein and whey proteinC57BL/6 mice, denervation/
Suppression muscle atrophy
Tachibana N
et al. [144]		miceSoy protein and red bell pepper juiceC57BL/6J mice, denervation/
Suppression of muscle atrophy and decrease atrogenes
Kakigi R
et al. [145]		HumansWhey proteinMale, Food intake, resistance exercise/
Mammalian target of rapamycin (mTOR) signaling activate
Tabata S
et al. [146]		miceisoflavonesICR mice, denervation/
Suppression muscle atrophy
Decrease in apoptosis-dependent signaling
Hirasaka K
et al. [147]		miceSoy isoflavonesC57BL/6J mice, denervation/
Resistance to muscle atrophy
Suppression of acetylcholine receptor disorders in denervating atrophic muscles
Aubertin-Leheudre M
et al. [149]		HumansisoflavonesSarcopenic-obese women, food intake/
Increase fat-free mass and muscle mass index
Mukai R
et al. [152]		mice8-Prenylnarin-geninC57/BL6 mice, denervation/suppress muscle atrophy
Increased phosphorylation of Akt
Suppression expression of Atrogin-1
Mukai R
et al. [158]		micequercetinC57BL/6J mice, tail suspension/
Suppression decrease muscle weight and express ubiquitin ligase
Mukai R
et al. [159]		micequercetinC57BL/6 mice, denervation/
Suppression muscle atrophy
Decrease Reactive oxygen species (ROS)
Increased phosphorylation of Akt
Saito K
et al. [163]		HumansVitamin CWomen, 70-84 years old/
Plasma vitamin C levels are positively correlated with grip strength, length of time standing on one leg with eyes open, and walking speed
Takisawa S
et al. [164]		miceVitamin CSPM30 knockout mice/
Muscle atrophy due to vitamin C deficiency, and recovery of muscle mass after vitamin C supplementation
Makanae Y
et al. [165]		ratsVitamin CWistar rats, overload/
suppression muscle hypertrophy on overload by administration of vitamin C
Ceglia L
et al. [166]		HumansVitamin DMobility-limited, vitamin D-insufficient women/
Increase muscle fiber by supplemental vitamin D
Endo I
et al. [167]		miceVitamin DVitamin D receptor (VDR) deletion mice/
Muscle fiber contraction by deletion of VDR
Visser M
et al. [168]		HumansVitamin D55–85 years old/
In humans with low serum vitamin D, lower grip test and tend to low appendicular skeletal muscle mass
Servais S
et al. [171]		ratsVitamin EWistar rats, hindlimb-suspend/
Suppression of muscle atrophy and decrease atrogenes
Ikemoto M
et al. [172]		ratsVitamin EWistar rats, tail suspension/
Supplemental vitamin E does not show effect of suppression muscle atrophy
Ito N
et al. [173]		micecapsaicinDenervation, hindlimb suspension/
Suppression of muscle atrophy by capsaicin injected intramuscularly
The table is summarized the literatures to investigate the function of natural compounds skeletal muscle metabolism.

7. Conclusions

The dynamics of muscle atrophy are complex and diverse. If food is effective in preventing skeletal muscle atrophy, it is safe and applicable to many people. The substances introduced this time can be candidates for treatment methods, but we think there are other beneficial substances. Animal models, including denervation models, are effective for elucidating molecular mechanisms and developing therapeutic substances. Further research focusing on foods against skeletal muscle atrophy is needed to study the mechanism of skeletal muscle atrophy.

Author Contributions

T.S., A.M., T.K., and S.K., writing the manuscript; S.K., study design; S.K., literature review, article preparation, and document submission. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

MyHCmyosin heavy chain
Myf5myogenic factor 5
MyoDmyoblast determination protein 1
Pax7paired box protein 7
Mesp1mesoderm posterior 1
ISl1insulin gene enhancer protein
IGF-1insulin-like growth factor 1
mTORmammalian target of rapamycin
mTORC1mammalian target of rapamycin complex 1
mTORC2mammalian target of rapamycin complex 2
PI3Kphosphoinositide 3-kinase
AMPadenosine monophosphate
AMPKadenosine monophosphate -activated protein kinase
eIF4Eeukaryotic translation initiation factor 4E
4EBP1eukaryotic translation initiation factor 4E-binding protein 1
S6K1ribosomal protein S6 kinase-1
IL-6interleukin-6
TGF-βtransforming growth factor β
FGFfibroblast growth factor
JAK2janus kinase 2
STAT3signal transducer and activator of transcription 3
MuRF-1muscle ring finger 1
Foxoforkhead box O
NF-ĸBnuclear factor kappa-light-chain-enhancer of activated B cells
TNF-αTumor necrosis factor α
JNKc-jun N-terminal kinase
PGC1-αperoxisome proliferator-activated receptor gamma coactivator 1
Cbl-bcasitas B-lineage lymphoma-b
IRS-1insulin receptor substrate-1
ActRIIBactivin type II B receptors
CDK2cyclin-dependent kinase 2
RJroyal jelly
10H2DAtrans-10-hydroxy-2-decenoic acid
10HDAA10-hydroxydecanoic acid
pRJprotease-treated royal jelly
HDAChistone deacetylase
GLUT4glucose transporter type 4
GGOHgeranylgeraniol
GRASgenerally recognized as safe
GGPPgeranylgeranylpyrophosphate
LPSlipopolysaccharide
ERestrogen receptors
ROSreactive oxygen species
TRPV1transient receptor potential vanilloid 1
VDRVitamin D receptor

References

  1. Rosenberg, I. Sarcopenia: Diagnosis and Mechanisms Sarcopenia: Origins and Clinical Relevance. Clin. Geriatr. Med. 2011, 27, 337–339. [Google Scholar] [CrossRef]
  2. Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyère, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, Y.; Sayer, A.A.; et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing 2019, 48, 16–31. [Google Scholar] [CrossRef] [Green Version]
  3. Biolo, G.; Cederholm, T.; Muscaritoli, M. Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: From sarcopenic obesity to cachexia. Clin. Nutr. 2014, 33, 737–748. [Google Scholar] [CrossRef] [PubMed]
  4. Tournadre, A.; Vial, G.; Capel, F.; Soubrier, M.; Boirie, Y. Sarcopenia. Jt. Bone Spine. 2019, 86, 309–314. [Google Scholar] [CrossRef] [PubMed]
  5. Mayhew, A.J.; Raina, P. Sarcopenia: New definitions, same limitations. Age Ageing 2019, 48, 613–614. [Google Scholar] [CrossRef]
  6. Gao, L.; Jiang, J.; Yang, M.; Hao, Q.; Luo, L.; Dong, B. Prevalence of Sarcopenia and Associated Factors in Chinese Community-Dwelling Elderly: Comparison Between Rural and Urban Areas. J. Am. Med. Dir. Assoc. 2015, 16, e1–e1003. [Google Scholar] [CrossRef]
  7. Tanaka, T.; Takahashi, K.; Hirano, H.; Kikutani, T.; Watanabe, Y.; Ohara, Y.; Furuya, H.; Tetsuo, T.; Akishita, M.; Iijima, K. Oral Frailty as a Risk Factor for Physical Frailty and Mortality in Community-Dwelling Elderly. J. Gerontol. Ser. A. 2018, 73, 1661–1667. [Google Scholar] [CrossRef]
  8. Cruz-Jentoft, A.J.; Sayer, A.A. Sarcopenia. Lancet 2019, 393, 2636–2646. [Google Scholar] [CrossRef]
  9. Moss, M.L.; Salentijn, L. The primary role of functional matrices in facial growth. Am. J. Orthod. 1969, 55, 566–577. [Google Scholar] [CrossRef]
  10. Howland, J.P.; Brodie, A.G. Pressures exerted by the buccinator muscle. Angle Orthod. 1966, 36, 1–12. [Google Scholar] [CrossRef] [PubMed]
  11. Tajbakhsh, S.; Rocancourt, D.; Cossu, G.; Buckingham, M. Redefining the Genetic Hierarchies Controlling Skeletal Myogenesis: Pax-3 and Myf-5 Act Upstream of MyoD. Cell 1997, 89, 127–138. [Google Scholar] [CrossRef] [Green Version]
  12. Kelly, R.G.; Jerome-Majewska, L.A.; Papaioannou, V.E. The del22q11.2 candidate gene Tbx1 regulates branchiomeric myogenesis. Hum. Mol. Genet. 2004, 13, 2829–2840. [Google Scholar] [CrossRef]
  13. Rios, A.C.; Marcelle, C. Head Muscles: Aliens Who Came in from the Cold? Dev. Cell. 2009, 16, 779–780. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Avis, V. The relation of the temporal muscle to the form of the coronoid process. Am. J. Phys. Anthropol. 1959, 17, 99–104. [Google Scholar] [CrossRef] [PubMed]
  15. Maki, K.; Miller, A.J.; Okano, T.; Hatcher, D.; Yamaguchi, T.; Kobayashi, H.; Shibasaki, Y. Cortical bone mineral density in asymmetrical mandibles: A three-dimensional quantitative computed tomography study. Eur. J. Orthod. 2001, 23, 217–232. [Google Scholar] [CrossRef] [PubMed]
  16. Becht, M.P.; Mah, J.; Martin, C.; Razmus, T.; Gunel, E.; Ngan, P. Evaluation of masseter muscle morphology in different types of malocclusions using cone beam computed tomography. Int. Orthod. 2014, 12, 32–48. [Google Scholar] [CrossRef]
  17. Avis, V. The significance of the angle of the mandible: An experimental and comparative study. Am. J. Phys. Anthropol. 1961, 19, 55–61. [Google Scholar] [CrossRef]
  18. Park, C.; Park, K.; Kim, J. Growth effects of botulinum toxin type A injected unilaterally into the masseter muscle of developing rats. J. Zhejiang Univ. B. 2015, 16, 46–51. [Google Scholar] [CrossRef] [PubMed]
  19. Gedrange, T.; Büttner, C.; Schneider, M.; Lauer, G.; Mai, R.; Oppitz, R.; Harzer, W. Change of mRNA amount of myosin heavy chain in masseter muscle after orthognathic surgery of patients with malocclusion. J. Cranio-Maxillofac. Surg. 2006, 34, 110–115. [Google Scholar] [CrossRef]
  20. Breuel, W.; Krause, M.; Schneider, M.; Harzer, W. Genetic stretching factors in masseter muscle after orthognathic surgery. Br. J. Oral Maxillofac. Surg. 2013, 51, 530–535. [Google Scholar] [CrossRef]
  21. Oukhai, K.; Maricic, N.; Schneider, M.; Harzer, W.; Tausche, E. Developmental myosin heavy chain mRNA in masseter after orthognathic surgery: A preliminary study. J. Cranio Maxillofac. Surg. 2011, 39, 401–406. [Google Scholar] [CrossRef] [PubMed]
  22. Proffit, W.R.; Phillips, C.; Dann, C.; Turvey, T.A. Stability after surgical-orthodontic correction of skeletal Class III malocclusion. I. Mandibular setback. Int. J. Adult Orthodon. Orthognath. Surg. 1991, 6, 7–18. [Google Scholar] [PubMed]
  23. Ayoub, A.F.; Trotman, C.A.; Stirrups, D.R.; Wilmot, J.J. Stability of bimaxillary osteotomy following surgical correction of class II skeletal deformities: A two-centre study. Br. J. Oral Maxillofac. Surg. 1997, 35, 107–115. [Google Scholar] [CrossRef]
  24. Hunt, N.P.; Cunningham, S.J. The influence of orthognathic surgery on occlusal force in patients with vertical facial deformities. Int. J. Oral Maxillofac. Surg. 1997, 26, 87–91. [Google Scholar] [CrossRef]
  25. Harzer, W.; Worm, M.; Gedrange, T.; Schneider, M.; Wolf, P. Myosin heavy chain mRNA isoforms in masseter muscle before and after orthognathic surgery. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontol. 2007, 104, 486–490. [Google Scholar] [CrossRef]
  26. Boyd, S.B.; Gonyea, W.J.; Legan, H.L.; Bell, W.H. Masseter muscle adaptation following surgical correction of vertical maxillary excess. J. Oral Maxillofac. Surg. 1989, 47, 953–962. [Google Scholar] [CrossRef]
  27. Maricic, N.; Stieler, E.; Gedrange, T.; Schneider, M.; Tausche, E.; Harzer, W. MGF- and myostatin-mRNA regulation in masseter muscle after orthognathic surgery. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontol. 2008, 106, 487–492. [Google Scholar] [CrossRef]
  28. Pette, D.; Staron, R.S. Mammalian Skeletal Muscle Fiber Type Transitions. Int. Rev. Cytol. 1997, 170, 143–223. [Google Scholar] [CrossRef]
  29. Roy, R.R.; Talmadge, R.J.; Hodgson, J.A.; Oishi, Y.; Baldwin, K.M.; Edgerton, V.R. Differential response of fast hindlimb extensor and flexor muscles to exercise in adult spinalized cats. Muscle Nerve 1999, 22, 230–241. [Google Scholar] [CrossRef]
  30. Harel, I.; Nathan, E.; Tirosh-Finkel, L.; Zigdon, H.; Guimarães-Camboa, N.; Evans, S.M.; Tzahor, E. Distinct Origins and Genetic Programs of Head Muscle Satellite Cells. Dev. Cell. 2009, 16, 822–832. [Google Scholar] [CrossRef] [Green Version]
  31. Yoshioka, K.; Kitajima, Y.; Seko, D.; Tsuchiya, Y.; Ono, Y. The body region specificity in murine models of muscle regeneration and atrophy. Acta Physiol. 2021, 231, 1–9. [Google Scholar] [CrossRef]
  32. Gojo, K.; Abe, S.; Ide, Y. Characteristics of Myofibres in the Masseter Muscle of Mice during Postnatal Growth Period. Anat. Histol. Embryol. 2002, 31, 105–112. [Google Scholar] [CrossRef]
  33. Mascarello, F.; Toniolo, L.; Cancellara, P.; Reggiani, C.; Maccatrozzo, L. Expression and identification of 10 sarcomeric MyHC isoforms in human skeletal muscles of different embryological origin. Diversity and similarity in mammalian species. Ann. Anat. 2016, 207, 9–20. [Google Scholar] [CrossRef]
  34. Schiaffino, S. Muscle fiber type diversity revealed by anti-myosin heavy chain antibodies. FEBS J. 2018, 285, 3688–3694. [Google Scholar] [CrossRef]
  35. Stedman, H.H.; Kozyak, B.W.; Nelson, A.; Thesier, D.M.; Su, L.T.; Low, D.W.; Bridges, C.R.; Shrager, J.B.; Minugh-Purvis, N.; Mitchell, M.A. Myosin gene mutation correlates with anatomical changes in the human lineage. Nature 2004, 428, 415–418. [Google Scholar] [CrossRef]
  36. Ono, Y.; Boldrin, L.; Knopp, P.; Morgan, J.E.; Zammit, P.S. Muscle satellite cells are a functionally heterogeneous population in both somite-derived and branchiomeric muscles. Dev. Biol. 2010, 337, 29–41. [Google Scholar] [CrossRef] [Green Version]
  37. Zoncu, R.; Efeyan, A.; Sabatini, D.M. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12, 21–35. [Google Scholar] [CrossRef] [Green Version]
  38. Guertin, D.A.; Stevens, D.M.; Thoreen, C.C.; Burds, A.A.; Kalaany, N.Y.; Moffat, J.; Brown, M.; Fitzgerald, K.J.; Sabatini, D.M. Ablation in Mice of the mTORC Components raptor, rictor, or mLST8 Reveals that mTORC2 Is Required for Signaling to Akt-FOXO and PKCα, but Not S6K1. Dev. Cell. 2006, 11, 859–871. [Google Scholar] [CrossRef] [Green Version]
  39. Shimobayashi, M.; Hall, M.N. Multiple amino acid sensing inputs to mTORC1. Cell Res. 2016, 26, 7–20. [Google Scholar] [CrossRef] [Green Version]
  40. Sengupta, S.; Peterson, T.R.; Sabatini, D.M. Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress. Mol. Cell. 2010, 40, 310–322. [Google Scholar] [CrossRef] [Green Version]
  41. Bazgir, B.; Fathi, R.; Valojerdi, M.R.; Mozdziak, P.; Asgari, A. Satellite cells contribution to exercise mediated muscle hypertrophy and repair. Cell J. 2016, 18, 473–484. [Google Scholar] [CrossRef]
  42. Hawke, T.J.; Garry, D.J. Myogenic satellite cells: Physiology to molecular biology. J. Appl. Physiol. 2001, 91, 534–551. [Google Scholar] [CrossRef]
  43. Kurosaka, M.; Machida, S. Interleukin-6-induced satellite cell proliferation is regulated by induction of the JAK2/STAT3 signalling pathway through cyclin D1 targeting. Cell Prolif. 2013, 46, 365–373. [Google Scholar] [CrossRef]
  44. Weissman, A.M.; Shabek, N.; Ciechanover, A. The predator becomes the prey: Regulating the ubiquitin system by ubiquitylation and degradation. Nat. Rev. Mol. Cell Biol. 2011, 12, 605–620. [Google Scholar] [CrossRef]
  45. Kamei, Y.; Miura, S.; Suzuki, M.; Kai, Y.; Mizukami, J.; Taniguchi, T.; Mochida, K.; Hata, T.; Matsuda, J.; Aburatani, H.; et al. Skeletal Muscle FOXO1 (FKHR) Transgenic Mice Have Less Skeletal Muscle Mass, Down-regulated Type I (Slow Twitch/Red Muscle) Fiber Genes, and Impaired Glycemic Control. J. Biol. Chem. 2004, 279, 41114–41123. [Google Scholar] [CrossRef] [Green Version]
  46. Bodine, S.C. Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy. Science 2001, 294, 1704–1708. [Google Scholar] [CrossRef]
  47. Bonaldo, P.; Sandri, M. Cellular and molecular mechanisms of muscle atrophy. Dis. Model. Mech. 2013, 6, 25–39. [Google Scholar] [CrossRef] [Green Version]
  48. Cai, D.; Frantz, J.D.; Tawa, N.E.; Melendez, P.A.; Oh, B.; Lidov, H.G.W.; Hasselgren, P.; Frontera, W.R.; Lee, J.; Glass, D.J.; et al. IKKβ/NF-κB Activation Causes Severe Muscle Wasting in Mice. Cell 2004, 119, 285–298. [Google Scholar] [CrossRef] [Green Version]
  49. Dogra, C.; Changoua, H.; Wedhas, N.; Qin, X.; Wergedal, J.E.; Kumar, A. TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J. 2007, 21, 1857–1869. [Google Scholar] [CrossRef] [Green Version]
  50. Draznin, B. Molecular mechanisms of insulin resistance: Serine phosphorylation of insulin receptor substrate-1 and increased expression of p85 α: The two sides of a coin. Diabetes 2006, 55, 2392–2397. [Google Scholar] [CrossRef] [Green Version]
  51. Sandri, M.; Lin, J.; Handschin, C.; Yang, W.; Arany, Z.P.; Lecker, S.H.; Goldberg, A.L.; Spiegelman, B.M. PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc. Natl. Acad. Sci. USA 2006, 103, 16260–16265. [Google Scholar] [CrossRef] [Green Version]
  52. Suzue, N.; Nikawa, T.; Onishi, Y.; Yamada, C.; Hirasaka, K.; Ogawa, T.; Furochi, H.; Kosaka, H.; Ishidoh, K.; Gu, H.; et al. Ubiquitin Ligase Cbl-b Downregulates Bone Formation Through Suppression of IGF-I Signaling in Osteoblasts During Denervation. J. Bone Miner. Res. 2006, 21, 722–734. [Google Scholar] [CrossRef] [Green Version]
  53. Nakao, R.; Hirasaka, K.; Goto, J.; Ishidoh, K.; Yamada, C.; Ohno, A.; Okumura, Y.; Nonaka, I.; Yasutomo, K.; Baldwin, K.M.; et al. Ubiquitin Ligase Cbl-b Is a Negative Regulator for Insulin-Like Growth Factor 1 Signaling during Muscle Atrophy Caused by Unloading. Mol. Cell. Biol. 2009, 29, 4798–4811. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Kirk, B.; Feehan, J.; Lombardi, G.; Duque, G. Muscle, Bone, and Fat Crosstalk: The Biological Role of Myokines, Osteokines, and Adipokines. Curr. Osteoporos. Rep. 2020, 18, 388–400. [Google Scholar] [CrossRef]
  55. Lee, S.-J. Regulation of Muscle Mass by Myostatin. Annu. Rev. Cell Dev. Biol. 2004, 20, 61–86. [Google Scholar] [CrossRef]
  56. Rodriguez, J.; Vernus, B.; Chelh, I.; Cassar-Malek, I.; Gabillard, J.C.; Hadj Sassi, A.; Seiliez, I.; Picard, B.; Bonnieu, A. Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways. Cell. Mol. Life Sci. 2014, 71, 4361–4371. [Google Scholar] [CrossRef]
  57. MacDonald, E.M.; Andres-Mateos, E.; Mejias, R.; Simmers, J.L.; Mi, R.; Park, J.-S.; Ying, S.; Hoke, A.; Lee, S.-J.; Cohn, R.D. Denervation atrophy is independent from Akt and mTOR activation and is not rescued by myostatin inhibition. Dis. Model. Mech. 2014, 7, 471–481. [Google Scholar] [CrossRef] [Green Version]
  58. Bodine, S.C.; Stitt, T.N.; Gonzalez, M.; Kline, W.O.; Stover, G.L.; Bauerlein, R.; Zlotchenko, E.; Scrimgeour, A.; Lawrence, J.C.; Glass, D.J.; et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 2001, 3, 1014–1019. [Google Scholar] [CrossRef]
  59. Grossman, E.J.; Roy, R.R.; Talmadge, R.J.; Zhong, H.; Edgerton, V.R. Effects of inactivity on myosin heavy chain composition and size of rat soleus fibers. Muscle Nerve 1998, 21, 375–389. [Google Scholar] [CrossRef]
  60. Borisov, A.B.; Dedkov, E.I.; Carlson, B.M. Interrelations of myogenic response, progressive atrophy of muscle fibers, and cell death in denervated skeletal muscle. Anat. Rec. 2001, 264, 203–218. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  61. Baek, K.W.; Jung, Y.K.; Kim, J.S.; Park, J.S.; Hah, Y.S.; Kim, S.J.; Yoo, J.-I. Rodent model of muscular atrophy for sarcopenia study. J. Bone Metab. 2020, 27, 97–110. [Google Scholar] [CrossRef]
  62. Zhao, J.; Brault, J.J.; Schild, A.; Cao, P.; Sandri, M.; Schiaffino, S.; Lecker, S.H.; Goldberg, A.L. FoxO3 Coordinately Activates Protein Degradation by the Autophagic/Lysosomal and Proteasomal Pathways in Atrophying Muscle Cells. Cell Metab. 2007, 6, 472–483. [Google Scholar] [CrossRef] [Green Version]
  63. Aweida, D.; Rudesky, I.; Volodin, A.; Shimko, E.; Cohen, S. GSK3-β promotes calpain-1–mediated desmin filament depolymerization and myofibril loss in atrophy. J. Cell Biol. 2018, 217, 3698–3714. [Google Scholar] [CrossRef] [Green Version]
  64. Wall, P.D.; Devor, M.; Inbal, R.; Scadding, J.W.; Schonfeld, D.; Seltzer, Z.; Tomkiewicz, M.M. Autotomy following peripheral nerve lesions: Experimental anesthesia dolorosa. Pain 1979, 7, 103–113. [Google Scholar] [CrossRef]
  65. Weinreb, M.; Rodan, G.A.; Thompson, D.D. Immobilization-related bone loss in the rat is increased by calcium deficiency. Calcif. Tissue Int. 1991, 48, 93–100. [Google Scholar] [CrossRef] [PubMed]
  66. Kirk, B.; Zanker, J.; Duque, G. Osteosarcopenia: Epidemiology, diagnosis, and treatment—Facts and numbers. J. Cachexia. Sarcopenia Muscle. 2020, 11, 609–618. [Google Scholar] [CrossRef] [Green Version]
  67. Martin, T.P.; Edgerton, V.R.; Grindeland, R.E. Influence of spaceflight on rat skeletal muscle. J. Appl. Physiol. 1988, 65, 2318–2325. [Google Scholar] [CrossRef]
  68. Bialek, P.; Morris, C.; Parkington, J.; St. Andre, M.; Owens, J.; Yaworsky, P.; Seeherman, H.; Jelinsky, S.A. Distinct protein degradation profiles are induced by different disuse models of skeletal muscle atrophy. Physiol. Genom. 2011, 43, 1075–1086. [Google Scholar] [CrossRef] [PubMed]
  69. Tang, H.; Inoki, K.; Lee, M.; Wright, E.; Khuong, A.; Khuong, A.; Sugiarto, S.; Garner, M.; Paik, J.; DePinho, R.A.; et al. mTORC1 Promotes Denervation-Induced Muscle Atrophy Through a Mechanism Involving the Activation of FoxO and E3 Ubiquitin Ligases. Sci. Signal. 2014, 7, ra18. [Google Scholar] [CrossRef] [PubMed]
  70. Olmstead, D.N.; Mesnard-Hoaglin, N.A.; Batka, R.J.; Haulcomb, M.M.; Miller, W.M.; Jones, K.J. Facial Nerve Axotomy in Mice: A Model to Study Motoneuron Response to Injury. J. Vis. Exp. 2015, 23, e52382. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  71. Tomlinson, B.E.; Irving, D. The numbers of limb motor neurons in the human lumbosacral cord throughout life. J. Neurol. Sci. 1977, 34, 213–219. [Google Scholar] [CrossRef]
  72. Oliveira, A.; Vaz, C. The role of sarcopenia in the risk of osteoporotic hip fracture. Clin. Rheumatol. 2015, 34, 1673–1680. [Google Scholar] [CrossRef] [PubMed]
  73. Waters, D.L.; Hale, L.; Grant, A.M.; Herbison, P.; Goulding, A. Osteoporosis and gait and balance disturbances in older sarcopenic obese New Zealanders. Osteoporos. Int. 2010, 21, 351–357. [Google Scholar] [CrossRef] [PubMed]
  74. Yu, R.; Leung, J.; Woo, J. Incremental Predictive Value of Sarcopenia for Incident Fracture in an Elderly Chinese Cohort: Results From the Osteoporotic Fractures in Men (MrOs) Study. J. Am. Med. Dir. Assoc. 2014, 15, 551–558. [Google Scholar] [CrossRef] [PubMed]
  75. Matsubara, Y.; Matsumoto, T.; Aoyagi, Y.; Tanaka, S.; Okadome, J.; Morisaki, K.; Shirabe, K.; Maehara, Y. Sarcopenia is a prognostic factor for overall survival in patients with critical limb ischemia. J. Vasc. Surg. 2015, 61, 945–950. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  76. Srikanthan, P.; Hevener, A.L.; Karlamangla, A.S. Sarcopenia Exacerbates Obesity-Associated Insulin Resistance and Dysglycemia: Findings from the National Health and Nutrition Examination Survey III. Earnest CP, ed. PLoS ONE 2010, 5, e10805. [Google Scholar] [CrossRef] [PubMed]
  77. Tolea, M.; Galvin, J. Sarcopenia and impairment in cognitive and physical performance. Clin. Interv. Aging. 2015, 10, 663–671. [Google Scholar] [CrossRef] [Green Version]
  78. Stene, G.B.; Helbostad, J.L.; Amundsen, T.; Sørhaug, S.; Hjelde, H.; Kaasa, S.; Grønberg, B.H. Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. Acta Oncol. 2015, 54, 340–348. [Google Scholar] [CrossRef]
  79. Harada, K.; Ida, S.; Baba, Y.; Ishimoto, T.; Kosumi, K.; Tokunaga, R.; Izumi, D.; Ohuchi, M.; Nakamura, K.; Kiyozumi, Y.; et al. Prognostic and clinical impact of sarcopenia in esophageal squamous cell carcinoma. Dis. Esophagus 2016, 29, 627–633. [Google Scholar] [CrossRef]
  80. Thoresen, L.; Frykholm, G.; Lydersen, S.; Ulveland, H.; Baracos, V.; Birdsell, L.; Falkmer, U. The association of nutritional assessment criteria with health-related quality of life in patients with advanced colorectal carcinoma. Eur. J. Cancer Care 2012, 21, 505–516. [Google Scholar] [CrossRef] [Green Version]
  81. Tsuchiya, Y.; Kitajima, Y.; Masumoto, H.; Ono, Y. Damaged Myofiber-Derived Metabolic Enzymes Act as Activators of Muscle Satellite Cells. Stem Cell Rep. 2020, 15, 926–940. [Google Scholar] [CrossRef] [PubMed]
  82. Ahmad, S.; Campos, M.G.; Fratini, F.; Altaye, S.Z.; Li, J. New Insights into the Biological and Pharmaceutical Properties of Royal Jelly. Int. J. Mol. Sci. 2020, 21, 382. [Google Scholar] [CrossRef] [Green Version]
  83. Khazaei, M.; Ansarian, A.; Ghanbari, E. New Findings on Biological Actions and Clinical Applications of Royal Jelly: A Review. J. Diet Suppl. 2018, 15, 757–775. [Google Scholar] [CrossRef]
  84. Inoue, S.; Koya-Miyata, S.; Ushio, S.; Iwaki, K.; Ikeda, M.; Kurimoto, M. Royal Jelly prolongs the life span of C3H/HeJ mice: Correlation with reduced DNA damage. Exp. Gerontol. 2003, 38, 965–969. [Google Scholar] [CrossRef]
  85. Honda, Y.; Fujita, Y.; Maruyama, H.; Araki, Y.; Ichihara, K.; Sato, A.; Kojima, T.; Tanaka, M.; Nozawa, Y.; Ito, M.; et al. Lifespan-Extending Effects of Royal Jelly and Its Related Substances on the Nematode Caenorhabditis elegans. PLoS ONE 2011, 6, e23527. [Google Scholar] [CrossRef] [Green Version]
  86. Kamakura, M.; Mitani, N.; Fukuda, T.; Fukushima, M. Antifatigue Effect of Fresh Royal Jelly in Mice. J. Nutr. Sci. Vitaminol. 2001, 47, 394–401. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  87. Viuda-Martos, M.; Ruiz-Navajas, Y.; Fernández-López, J.; Pérez-Álvarez, J.A. Functional Properties of Honey, Propolis, and Royal Jelly. J. Food Sci. 2008, 73, R117–R124. [Google Scholar] [CrossRef]
  88. Liu, J.-R.; Yang, Y.-C.; Shi, L.-S.; Peng, C.-C. Antioxidant Properties of Royal Jelly Associated with Larval Age and Time of Harvest. J. Agric. Food Chem. 2008, 56, 11447–11452. [Google Scholar] [CrossRef]
  89. Kohno, K.; Okamoto, I.; Sano, O.; Arai, N.; Iwaki, K.; Ikeda, M.; Kurimoto, M. Royal Jelly Inhibits the Production of Proinflammatory Cytokines by Activated Macrophages. Biosci. Biotechnol. Biochem. 2004, 68, 138–145. [Google Scholar] [CrossRef] [Green Version]
  90. Vittek, J. Effect of Royal Jelly on serum lipids in experimental animals and humans with atherosclerosis. Experientia 1995, 51, 927–935. [Google Scholar] [CrossRef]
  91. Isidorov, V.A.; Bakier, S.; Grzech, I. Gas chromatographic–mass spectrometric investigation of volatile and extractable compounds of crude royal jelly. J. Chromatogr. B. 2012, 885–886, 109–116. [Google Scholar] [CrossRef]
  92. Townsend, G.F.; Brown, W.H.; Felauer, E.E.; Hazlett, B. Studies on the in vitro antitumor activity of fatty acids. IV. The esters of acids closely related to 10-hydroxy-2-decenoic acids from royal jelly against transplantable mouse leukemia. Can. J. Biochem. Physiol. 1961, 39, 1765–1770. [Google Scholar] [CrossRef]
  93. Maeda, T.; Kuroda, H.; Motoyoshi, K. Effects of royal jelly and 10-hydroxy decenoic acid on the sebaceous glands of hamster ear. Jpn. J. Dermatol. 1988, 98, 469–475. [Google Scholar]
  94. Koya-Miyata, S.; Okamoto, I.; Ushio, S.; Iwaki, K.; Ikeda, M.; Kurimoto, M. Identification of a Collagen Production-promoting Factor from an Extract of Royal Jelly and Its Possible Mechanism. Biosci. Biotechnol. Biochem. 2004, 68, 767–773. [Google Scholar] [CrossRef] [PubMed]
  95. Blum, M.S.; Novak, A.F.; Taber, S. 10-Hydroxy-Dgr2-Decenoic Acid, an Antibiotic Found in Royal Jelly. Science 1959, 130, 452–453. [Google Scholar] [CrossRef]
  96. Ito, S.; Nitta, Y.; Fukumitsu, H.; Soumiya, H.; Ikeno, K.; Nakamura, T.; Furukawa, S. Antidepressant-Like Activity of 10-Hydroxy-Trans-2-Decenoic Acid, a Unique Unsaturated Fatty Acid of Royal Jelly, in Stress-Inducible Depression-Like Mouse Model. Evid. Based Complement. Altern. Med. 2012, 2012, 1–6. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  97. Niu, K.; Guo, H.; Guo, Y.; Ebihara, S.; Asada, M.; Ohrui, T.; Furukawa, K.; Ichinose, M.; Yanai, K.; Kudo, Y.; et al. Royal Jelly Prevents the Progression of Sarcopenia in Aged Mice In Vivo and In Vitro. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 2013, 68, 1482–1492. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  98. Takahashi, Y.; Hijikata, K.; Seike, K.; Nakano, S.; Banjo, M.; Sato, Y.; Takahashi, K.; Hatta, H. Effects of Royal Jelly Administration on Endurance Training-Induced Mitochondrial Adaptations in Skeletal Muscle. Nutrients 2018, 10, 1735. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  99. Shirakawa, T.; Miyawaki, A.; Matsubara, T.; Okumura, N.; Okamoto, H.; Nakai, N.; Rojasawasthien, T.; Morikawa, K.; Inoue, A.; Goto, A.; et al. Daily Oral Administration of Protease-Treated Royal Jelly Protects Against Denervation-Induced Skeletal Muscle Atrophy. Nutrients 2020, 12, 3089. [Google Scholar] [CrossRef]
  100. Okumura, N.; Toda, T.; Ozawa, Y.; Watanabe, K.; Ikuta, T.; Tatefuji, T.; Hashimoto, K.; Shimizu, T. Royal Jelly Delays Motor Functional Impairment During Aging in Genetically Heterogeneous Male Mice. Nutrients 2018, 10, 1191. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  101. Maleszka, R. Epigenetic integration of environmental and genomic signals in honey bees: The critical interplay of nutritional, brain and reproductive networks. Epigenetics 2008, 3, 188–192. [Google Scholar] [CrossRef] [Green Version]
  102. Spannhoff, A.; Kim, Y.K.; Raynal, N.J.-M.; Gharibyan, V.; Su, M.; Zhou, Y.; Li, J.; Castellano, S.; Sbardella, G.; Issa, J.J.; et al. Histone deacetylase inhibitor activity in royal jelly might facilitate caste switching in bees. EMBO Rep. 2011, 12, 238–243. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  103. Montesano, A.; Luzi, L.; Senesi, P.; Terruzzi, I. Modulation of Cell Cycle Progression by 5-Azacytidine Is Associated with Early Myogenesis Induction in Murine Myoblasts. Int. J. Biol. Sci. 2013, 9, 391–402. [Google Scholar] [CrossRef] [Green Version]
  104. Hupkes, M.; Jonsson, M.K.B.; Scheenen, W.J.; Rotterdam, W.; Sotoca, A.M.; Someren, E.P.; Heyden, M.A.G.; Veen, T.A.; Ravestein-van Os, R.I.; Bauerschmidt, S.; et al. Epigenetics: DNA demethylation promotes skeletal myotube maturation. FASEB J. 2011, 25, 3861–3872. [Google Scholar] [CrossRef] [PubMed]
  105. Murray, R.L.; Zhang, W.; Iwaniuk, M.; Grilli, E.; Stahl, C.H. Dietary tributyrin, an HDAC inhibitor, promotes muscle growth through enhanced terminal differentiation of satellite cells. Physiol. Rep. 2018, 6, e13706. [Google Scholar] [CrossRef] [PubMed]
  106. Fan, H.; Zhang, R.; Tesfaye, D.; Tholen, E.; Looft, C.; Hölker, M.; Schellander, K.; Cinar, M.U. Sulforaphane causes a major epigenetic repression of myostatin in porcine satellite cells. Epigenetics 2012, 7, 1379–1390. [Google Scholar] [CrossRef] [Green Version]
  107. Fisher, J.S.; Gao, J.; Han, D.; Holloszy, J.O.; Nolte, L.A. Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. Am. J. Physiol. Metab. 2002, 282, E18–E23. [Google Scholar] [CrossRef] [PubMed]
  108. Takikawa, M.; Kumagai, A.; Hirata, H.; Soga, M.; Yamashita, Y.; Ueda, M.; Ashida, H.; Tsuda, T. 10-Hydroxy-2-decenoic acid, a unique medium-chain fatty acid, activates 5’-AMP-activated protein kinase in L6 myotubes and mice. Mol. Nutr. Food Res. 2013, 57, 1794–1802. [Google Scholar] [CrossRef]
  109. Muraguchi, T.; Okamoto, K.; Mitake, M.; Ogawa, H.; Shidoji, Y. Polished rice as natural sources of cancer-preventing geranylgeranoic acid. J. Clin. Biochem. Nutr. 2011, 49, 8–15. [Google Scholar] [CrossRef] [Green Version]
  110. Matsubara, T.; Urata, M.; Nakajima, T.; Fukuzaki, M.; Masuda, R.; Yoshimoto, Y.; Addison, W.N.; Nakatomi, C.; Morikawa, K.; Zhang, M.; et al. Geranylgeraniol-induced Myogenic Differentiation of C2C12 Cells. In Vivo 2018, 32, 1427–1431. [Google Scholar] [CrossRef] [Green Version]
  111. Miyawaki, A.; Rojasawasthien, T.; Hitomi, S.; Aoki, Y.; Urata, M.; Inoue, A.; Matsubara, T.; Morikawa, K.; Habu, M.; Tominaga, K.; et al. Oral Administration of Geranylgeraniol Rescues Denervation-induced Muscle Atrophy via Suppression of Atrogin-1. In Vivo 2020, 34, 2345–2351. [Google Scholar] [CrossRef] [PubMed]
  112. Bodine, S.C.; Baehr, L.M. Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1. Am. J. Physiol. Metab. 2014, 307, E469–E484. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  113. Judge, A.R.; Koncarevic, A.; Hunter, R.B.; Liou, H.; Jackman, R.W.; Kandarian, S.C. Role for IκBα, but not c-Rel, in skeletal muscle atrophy. Am. J. Physiol. Physiol. 2007, 292, C372–C382. [Google Scholar] [CrossRef] [Green Version]
  114. Gammeren, D.; Damrauer, J.S.; Jackman, R.W.; Kandarian, S.C. The IκB kinases IKKα and IKKβ are necessary and sufficient for skeletal muscle atrophy. FASEB J. 2009, 23, 362–370. [Google Scholar] [CrossRef]
  115. Mourkioti, F.; Kratsios, P.; Luedde, T.; Song, Y.; Delafontaine, P.; Adami, R.; Parente, V.; Bottinelli, R.; Pasparakis, M.; Rosenthal, N. Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. J. Clin. Investig. 2006, 116, 2945–2954. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  116. Bar-Shai, M.; Carmeli, E.; Ljubuncic, P.; Reznick, A.Z. Exercise and immobilization in aging animals: The involvement of oxidative stress and NF-κB activation. Free Radic. Biol. Med. 2008, 44, 202–214. [Google Scholar] [CrossRef] [PubMed]
  117. Rhoads, M.G.; Kandarian, S.C.; Pacelli, F.; Doglietto, G.B.; Bossola, M. Expression of NF-κB and IκB proteins in skeletal muscle of gastric cancer patients. Eur. J. Cancer. 2010, 46, 191–197. [Google Scholar] [CrossRef] [Green Version]
  118. Wu, C.; Kandarian, S.C.; Jackman, R.W. Identification of Genes that Elicit Disuse Muscle Atrophy via the Transcription Factors p50 and Bcl-3. PLoS ONE 2011, 6, e16171. [Google Scholar] [CrossRef] [Green Version]
  119. Giriwono, P.E.; Shirakawa, H.; Ohsaki, Y.; Hata, S.; Kuriyama, H.; Sato, S.; Goto, T.; Komai, M. Dietary supplementation with geranylgeraniol suppresses lipopolysaccharide-induced inflammation via inhibition of nuclear factor-κB activation in rats. Eur. J. Nutr. 2013, 52, 1191–1199. [Google Scholar] [CrossRef] [PubMed]
  120. Giriwono, P.E.; Shirakawa, H.; Ohsaki, Y.; Sato, S.; Aoyama, Y.; Ho, H.-J.; Goto, T.; Komai, M. Geranylgeraniol Suppresses the Expression of IRAK1 and TRAF6 to Inhibit NFκB Activation in Lipopolysaccharide-Induced Inflammatory Responses in Human Macrophage-Like Cells. Int. J. Mol. Sci. 2019, 20, 2320. [Google Scholar] [CrossRef] [Green Version]
  121. Ho, H.; Shirakawa, H.; Yoshida, R.; Ito, A.; Maeda, M.; Goto, T.; Komai, M. Geranylgeraniol enhances testosterone production via the cAMP/protein kinase A pathway in testis-derived I-10 tumor cells. Biosci. Biotechnol. Biochem. 2016, 80, 791–797. [Google Scholar] [CrossRef] [Green Version]
  122. Carson, J.A.; Manolagas, S.C. Effects of sex steroids on bones and muscles: Similarities, parallels, and putative interactions in health and disease. Bone 2015, 80, 67–78. [Google Scholar] [CrossRef] [Green Version]
  123. Hourdé, C.; Jagerschmidt, C.; Clément-Lacroix, P.; Vignaud, A.; Ammann, P.; Butler-Browne, G.S.; Ferry, A. Androgen replacement therapy improves function in male rat muscles independently of hypertrophy and activation of the Akt/mTOR pathway. Acta Physiol. 2009, 195, 471–482. [Google Scholar] [CrossRef]
  124. Pires-Oliveira, M.; Maragno, A.L.G.C.; Parreiras-e-Silva, L.T.; Chiavegatti, T.; Gomes, M.D.; Godinho, R.O. Testosterone represses ubiquitin ligases atrogin-1 and Murf-1 expression in an androgen-sensitive rat skeletal muscle in vivo. J. Appl. Physiol. 2010, 108, 266–273. [Google Scholar] [CrossRef] [Green Version]
  125. Tikkanen, M.J.; Nikkilä, E.A. Current pharmacologic treatment of elevated serum cholesterol. Circulation 1987, 76, 529–533. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  126. Illingworth, D.R.; Sexton, G.J. Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia. J. Clin. Investig. 1984, 74, 1972–1978. [Google Scholar] [CrossRef] [PubMed]
  127. Hoeg, J.M.; Maher, M.B.; Zech, L.A.; Bailey, K.R.; Gregg, R.E.; Lackner, K.J.; Fojo, S.S.; Anchors, M.A.; Bojanovski, M.; Sprecher, D.L.; et al. Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia. Am. J. Cardiol. 1986, 57, 933–939. [Google Scholar] [CrossRef]
  128. Grundy, S.M.; Vega, G.L. Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia. J. Lipid Res. 1985, 26, 1464–1475. [Google Scholar] [CrossRef]
  129. Paul, D.; Thompson, M.D.; Clarkson, P.; Richard, H.K. Statin-Associated Myopathy. JAMA 2003, 289, 1681–1690. [Google Scholar] [CrossRef]
  130. Pasternak, R.C.; Smith, S.C.; Bairey-Merz, C.N.; Grundy, S.M.; Cleeman, J.I.; Lenfant, C.; Hon, F. ACC/AHA/NHLBI Clinical Advisory on Statins. Circulation 2002, 106, 1024–1028. [Google Scholar] [CrossRef] [PubMed]
  131. McKenney, J.M.; Davidson, M.H.; Jacobson, T.A.; Guyton, J.R. Final Conclusions and Recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am. J. Cardiol. 2006, 97, 89C–94C. [Google Scholar] [CrossRef] [PubMed]
  132. Sathasivam, S. Statin induced myotoxicity. Eur. J. Intern. Med. 2012, 23, 317–324. [Google Scholar] [CrossRef] [PubMed]
  133. Bhardwaj, S.; Selvarajah, S.; Schneider, E.B. Muscular effects of statins in the elderly female: A review. Clin. Interv. Aging. 2013, 8, 47–59. [Google Scholar] [CrossRef] [Green Version]
  134. Nishimoto, T.; Tozawa, R.; Amano, Y.; Wada, T.; Imura, Y.; Sugiyama, Y. Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes. Biochem. Pharmacol. 2003, 66, 2133–2139. [Google Scholar] [CrossRef]
  135. Matzno, S.; Yamauchi, T.; Gohda, M.; Ishida, N.; Katsuura, K.; Hanasaki, Y.; Tokunaga, T.; Itoh, H.; Nakamura, N. Inhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblasts. J. Lipid Res. 1997, 38, 1639–1648. [Google Scholar] [CrossRef]
  136. Baba, T.T.; Nemoto, T.K.; Miyazaki, T.; Oida, S. Simvastatin suppresses the differentiation of C2C12 myoblast cells via a Rac pathway. J. Muscle Res. Cell Motil. 2008, 29, 127–134. [Google Scholar] [CrossRef] [Green Version]
  137. Cao, P.; Hanai, J.; Tanksale, P.; Imamura, S.; Sukhatme, V.P.; Lecker, S.H. Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect. FASEB J. 2009, 23, 2844–2854. [Google Scholar] [CrossRef] [Green Version]
  138. Report of the Subdivision on Resources, The Council for Science and Technology, Ministry of Education, Culture, Sports, Science and Technology, Japan. Standard Tables of Food Composition In Japan—2020—(Eighth Revised Edition). Available online: https://www.mext.go.jp/content/20201225-mxt_kagsei-mext_01110_011.pdf (accessed on 21 June 2021).
  139. Hashimoto, R.; Sakai, A.; Murayama, M.; Ochi, A.; Abe, T.; Hirasaka, K.; Ohno, A.; Teshima-Kondo, S.; Yanagawa, H.; Yasui, N.; et al. Effects of dietary soy protein on skeletal muscle volume and strength in humans with various physical activities. J. Med. Investig. 2015, 62, 177–183. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  140. Kitajima, Y.; Ogawa, S.; Egusa, S.; Ono, Y. Soymilk Improves Muscle Weakness in Young Ovariectomized Female Mice. Nutrients 2017, 9, 834. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  141. Samoto, M.; Maebuchi, M.; Miyazaki, C.; Kugitani, H.; Kohno, M.; Hirotsuka, M.; Kito, M. Abundant proteins associated with lecithin in soy protein isolate. Food Chem. 2007, 102, 317–322. [Google Scholar] [CrossRef]
  142. Abe, T.; Kohno, S.; Yama, T.; Ochi, A.; Suto, T.; Hirasaka, K.; Ohno, A.; Teshima-Kondo, S.; Okumura, Y.; Oarada, M.; et al. Soy Glycinin Contains a Functional Inhibitory Sequence against Muscle-Atrophy-Associated Ubiquitin Ligase Cbl-b. Int. J. Endocrinol. 2013, 2013, 1–11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  143. Nikawa, T.; Hashimoto, R.; Nakao, R.; Uchida, T.; Ninomiya, M.; Kimori, Y.; Maita, A.; Tetsuno, A.; Ida, K.; Kishimoto, H.; et al. Effects of Dietary Soy Protein and Whey Protein on Denervation-induced Skeletal Muscle Atrophy. Soy Protein Res. Jpn. 2017, 20, 8–12. [Google Scholar]
  144. Tachibana, N.; Fukao, M.; Irie, T.; Irisawa, Y.; Shirono, H.; Oarada, M.; Nikawa, T.; Fukaya, T. A Diet Including Red Bell Pepper Juice and Soy Protein Suppress Physiological Markers of Muscle Atrophy in Mice. J. Nutr. Sci. Vitaminol. 2020, 66, 449–455. [Google Scholar] [CrossRef] [PubMed]
  145. Kakigi, R.; Yoshihara, T.; Ozaki, H.; Ogura, Y.; Ichinoseki-Sekine, N.; Kobayashi, H.; Naito, H. Whey protein intake after resistance exercise activates mTOR signaling in a dose-dependent manner in human skeletal muscle. Eur. J. Appl. Physiol. 2014, 114, 735–742. [Google Scholar] [CrossRef] [PubMed]
  146. Tabata, S.; Aizawa, M.; Kinoshita, M.; Ito, Y.; Kawamura, Y.; Takebe, M.; Pan, W.; Sakuma, K. The influence of isoflavone for denervation-induced muscle atrophy. Eur. J. Nutr. 2019, 58, 291–300. [Google Scholar] [CrossRef]
  147. Hirasaka, K.; Maeda, T.; Haruna, M.; Abe, T.; Ochi, A.; Ohno-Maita, A.; Teshima-Kondo, S.; Taniyama, S.; Tachibana, K.; Nikawa, T. Effects of Isoflavones Derived from Soy Beans on Muscle Atrophy. Soy Protein Res. Jpn. 2014, 17, 150–155. [Google Scholar]
  148. Hirasaka, K.; Maeda, T.; Ikeda, C.; Haruna, M.; Kohno, S.; Abe, T.; Ochi, A.; Mukai, R.; Oarada, M.; Eshima-Kondo, S.; et al. Isoflavones Derived from Soy Beans Prevent MuRF1-Mediated Muscle Atrophy in C2C12 Myotubes through SIRT1 Activation. J. Nutr. Sci. Vitaminol. 2013, 59, 317–324. [Google Scholar] [CrossRef] [Green Version]
  149. Aubertin-Leheudre, M.; Lord, C.; Khalil, A.; Dionne, I.J. Six months of isoflavone supplement increases fat-free mass in obese–sarcopenic postmenopausal women: A randomized double-blind controlled trial. Eur. J. Clin. Nutr. 2007, 61, 1442–1444. [Google Scholar] [CrossRef]
  150. Harris, D.M.; Besselink, E.; Henning, S.M.; Go, V.L.W.; Heber, D. Phytoestrogens Induce Differential Estrogen Receptor Alpha- or Beta-Mediated Responses in Transfected Breast Cancer Cells. Exp. Biol. Med. 2005, 230, 558–568. [Google Scholar] [CrossRef]
  151. Seko, D.; Fujita, R.; Kitajima, Y.; Nakamura, K.; Imai, Y.; Ono, Y. Estrogen Receptor β Controls Muscle Growth and Regeneration in Young Female Mice. Stem Cell Rep. 2020, 15, 577–586. [Google Scholar] [CrossRef] [PubMed]
  152. Mukai, R.; Horikawa, H.; Fujikura, Y.; Kawamura, T.; Nemoto, H.; Nikawa, T.; Terao, J. Prevention of Disuse Muscle Atrophy by Dietary Ingestion of 8-Prenylnaringenin in Denervated Mice. PLoS ONE 2012, 7, e45048. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  153. Al Shahrani, M.; Heales, S.; Hargreaves, I.; Orford, M. Oxidative Stress: Mechanistic Insights into Inherited Mitochondrial Disorders and Parkinson’s Disease. J. Clin. Med. 2017, 6, 100. [Google Scholar] [CrossRef]
  154. Davalli, P.; Mitic, T.; Caporali, A.; Lauriola, A.; D’Arca, D. ROS, Cell Senescence, and Novel Molecular Mechanisms in Aging and Age-Related Diseases. Oxid. Med. Cell. Longev. 2016, 2016, 1–18. [Google Scholar] [CrossRef] [Green Version]
  155. He, F.; Zuo, L. Redox Roles of Reactive Oxygen Species in Cardiovascular Diseases. Int. J. Mol. Sci. 2015, 16, 27770–27780. [Google Scholar] [CrossRef] [Green Version]
  156. Gloire, G.; Legrand-Poels, S.; Piette, J. NF-κB activation by reactive oxygen species: Fifteen years later. Biochem. Pharmacol. 2006, 72, 1493–1505. [Google Scholar] [CrossRef]
  157. Hori, Y.S.; Kuno, A.; Hosoda, R.; Horio, Y. Regulation of FOXOs and p53 by SIRT1 Modulators under Oxidative Stress. PLoS ONE 2013, 8, e73875. [Google Scholar] [CrossRef]
  158. Mukai, R.; Nakao, R.; Yamamoto, H.; Nikawa, T.; Takeda, E.; Terao, J. Quercetin Prevents Unloading-Derived Disused Muscle Atrophy by Attenuating the Induction of Ubiquitin Ligases in Tail-Suspension Mice. J. Nat. Prod. 2010, 73, 1708–1710. [Google Scholar] [CrossRef] [PubMed]
  159. Mukai, R.; Matsui, N.; Fujikura, Y.; Matsumoto, N.; Hou, D.; Kanzaki, N.; Shibata, H.; Horikawa, M.; Iwasa, K.; Hirasaka, K.; et al. Preventive effect of dietary quercetin on disuse muscle atrophy by targeting mitochondria in denervated mice. J. Nutr. Biochem. 2016, 31, 67–76. [Google Scholar] [CrossRef]
  160. Nakamura, S. Chemistry of Reactive Oxygen Species and Antioxidants. J. Nippon Med. Sch. 2013, 9, 164–169. [Google Scholar]
  161. Chen, Q.; Espey, M.G.; Sun, A.Y.; Lee, J.-H.; Krishna, M.C.; Shacter, E.; Choyke, P.L.; Pooput, C.; Kirk, K.L.; Buettner, G.R.; et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc. Natl. Acad. Sci. USA 2007, 104, 8749–8754. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  162. Blaszczak, W.; Barczak, W.; Masternak, J.; Kopczyński, P.; Zhitkovich, A.; Rubiś, B. Vitamin C as a Modulator of the Response to Cancer Therapy. Molecules 2019, 24, 453. [Google Scholar] [CrossRef] [Green Version]
  163. Saito, K.; Yokoyama, T.; Yoshida, H.; Kim, H.; Shimada, H.; Yoshida, Y.; Iwasa, H.; Shimizu, Y.; Kondo, Y.; Handa, S.; et al. A Significant Relationship between Plasma Vitamin C Concentration and Physical Performance among Japanese Elderly Women. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 2012, 67, 295–301. [Google Scholar] [CrossRef]
  164. Takisawa, S.; Funakoshi, T.; Yatsu, T.; Nagata, K.; Aigaki, T.; Machida, S.; Ishigami, A. Vitamin C deficiency causes muscle atrophy and a deterioration in physical performance. Sci. Rep. 2019, 9, 4702. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  165. Makanae, Y.; Kawada, S.; Sasaki, K.; Nakazato, K.; Ishii, N. Vitamin C administration attenuates overload-induced skeletal muscle hypertrophy in rats. Acta Physiol. 2013, 208, 57–65. [Google Scholar] [CrossRef]
  166. Ceglia, L.; Niramitmahapanya, S.; da Silva Morais, M.; Rivas, D.A.; Harris, S.S.; Bischoff-Ferrari, H.; Fielding, R.A.; Dawson-Hughes, B. A Randomized Study on the Effect of Vitamin D 3 Supplementation on Skeletal Muscle Morphology and Vitamin D Receptor Concentration in Older Women. J. Clin. Endocrinol. Metab. 2013, 98, E1927–E1935. [Google Scholar] [CrossRef] [Green Version]
  167. Endo, I.; Inoue, D.; Mitsui, T.; Umaki, Y.; Akaike, M.; Yoshizawa, T.; Kato, S.; Matsumoto, T. Deletion of Vitamin D Receptor Gene in Mice Results in Abnormal Skeletal Muscle Development with Deregulated Expression of Myoregulatory Transcription Factors. Endocrinology 2003, 144, 5138–5144. [Google Scholar] [CrossRef] [Green Version]
  168. Visser, M.; Deeg, D.J.H.; Lips, P. Low Vitamin D and High Parathyroid Hormone Levels as Determinants of Loss of Muscle Strength and Muscle Mass (Sarcopenia): The Longitudinal Aging Study Amsterdam. J. Clin. Endocrinol. Metab. 2003, 88, 5766–5772. [Google Scholar] [CrossRef] [PubMed]
  169. Beaudart, C.; Buckinx, F.; Rabenda, V.; Gillain, S.; Cavalier, E.; Slomian, J.; Petermans, J.; Reginster, J.-Y.; Bruyère, O. The Effects of Vitamin D on Skeletal Muscle Strength, Muscle Mass, and Muscle Power: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J. Clin. Endocrinol. Metab. 2014, 99, 4336–4345. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  170. Hirose, Y.; Onishi, T.; Miura, S.; Hatazawa, Y.; Kamei, Y. Vitamin D Attenuates FOXO1-Target Atrophy Gene Expression in C2C12 Muscle Cells. J. Nutr. Sci. Vitaminol. 2018, 64, 229–232. [Google Scholar] [CrossRef] [Green Version]
  171. Servais, S.; Letexier, D.; Favier, R.; Duchamp, C.; Desplanches, D. Prevention of unloading-induced atrophy by vitamin E supplementation: Links between oxidative stress and soleus muscle proteolysis? Free Radic. Biol. Med. 2007, 42, 627–635. [Google Scholar] [CrossRef] [Green Version]
  172. Ikemoto, M.; Okamura, Y.; Kano, M.; Hirasaka, K.; Tanaka, R.; Yamamoto, T.; Sasa, T.; Ogawa, T.; Sairyo, K.; Kishi, K.; et al. A Relative High Dose of Vitamin E Does Not Attenuate Unweighting-Induced Oxidative Stress and Ubiquitination in Rat Skeletal Muscle. J. Physiol. Anthropol. Appl. Human Sci. 2002, 21, 257–263. [Google Scholar] [CrossRef] [PubMed]
  173. Ito, N.; Ruegg, U.T.; Kudo, A.; Miyagoe-Suzuki, Y.; Takeda, S. Activation of calcium signaling through Trpv1 by nNOS and peroxynitrite as a key trigger of skeletal muscle hypertrophy. Nat. Med. 2013, 19, 101–106. [Google Scholar] [CrossRef] [PubMed]
Ijms 22 08310 g001 550
Figure 1. Relationship between dentition and facial muscles. (A) The muscles run vertically and horizontally on the face. (B) The teeth move to the position where the pressure is balanced. The dentition receives muscle pressure medially from the tongue muscles and laterally from the orbicularis oris and buccinator muscles. Orthodontists perform myofunctional therapy because abnormal oral habits (e.g., infant-type swallowing and tongue thrusting habit) adversely affect the dentition.
Figure 1. Relationship between dentition and facial muscles. (A) The muscles run vertically and horizontally on the face. (B) The teeth move to the position where the pressure is balanced. The dentition receives muscle pressure medially from the tongue muscles and laterally from the orbicularis oris and buccinator muscles. Orthodontists perform myofunctional therapy because abnormal oral habits (e.g., infant-type swallowing and tongue thrusting habit) adversely affect the dentition.
Ijms 22 08310 g001
Ijms 22 08310 g002 550
Figure 2. Muscle remodeling cycle.
Figure 2. Muscle remodeling cycle.
Ijms 22 08310 g002
Ijms 22 08310 g003 550
Figure 3. Schematic overview of the effective natural compounds in muscle remodeling cycle.
Figure 3. Schematic overview of the effective natural compounds in muscle remodeling cycle.
Ijms 22 08310 g003
Table
Table 1. Comparison of myosin heavy chain isoform.
Table 1. Comparison of myosin heavy chain isoform.
GenesProteinsCharacteristics
MYH 1MyHC 2xFast type 2x fibers
MYH 2MyHC 2aFast type 2a fibers
MYH 3MyHC EMBDeveloping muscle, Extraocular muscles
MYH 4MyHC 2bFast type 2b fibers
MYH 6MyHC αHeart and jaw muscles
MYH 7MyHC βHeart and slow muscles, type 1 fibers
MYH 7bMyHC slow tonicExtraocular muscles
MYH 8MyHC NEODeveloping muscle, expression in masseter muscles
MYH 13MyHC EOExtraocular muscles
MYH 15MyHC 15Extraocular muscles
MYH 16MyHC 16Jaw muscles (in human, translation is blocked)
Each Myosin heavy chain (MyHC) isoform has own characteristics and is different to expression depending on the location and timing of muscles.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Shirakawa, T.; Miyawaki, A.; Kawamoto, T.; Kokabu, S. Natural Compounds Attenuate Denervation-Induced Skeletal Muscle Atrophy. Int. J. Mol. Sci. 2021, 22, 8310. https://doi.org/10.3390/ijms22158310

AMA Style

Shirakawa T, Miyawaki A, Kawamoto T, Kokabu S. Natural Compounds Attenuate Denervation-Induced Skeletal Muscle Atrophy. International Journal of Molecular Sciences. 2021; 22(15):8310. https://doi.org/10.3390/ijms22158310

Chicago/Turabian Style

Shirakawa, Tomohiko, Aki Miyawaki, Tatsuo Kawamoto, and Shoichiro Kokabu. 2021. "Natural Compounds Attenuate Denervation-Induced Skeletal Muscle Atrophy" International Journal of Molecular Sciences 22, no. 15: 8310. https://doi.org/10.3390/ijms22158310

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop